Moderna Inc
MRNA26.670USD
-0.680-2.49%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
10.32BValor de mercado
PerdaP/L TTM
Mais detalhes de Moderna Inc Empresa
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Informações da empresa
Código da empresaMRNA
Nome da EmpresaModerna Inc
Data de listagemDec 07, 2018
Fundado em2016
CEOMr. Stephane Bancel
Número de funcionários5800
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 07
Endereço325 Binney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone16177146500
Sitehttps://www.modernatx.com/
Código da empresaMRNA
Data de listagemDec 07, 2018
Fundado em2016
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.19K
+3.64%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.19K
+3.64%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
COVID
3.08B
99.20%
RSV
25.00M
0.80%
Por RegiãoUSD
Nome
Receita
Proporção
United States
1.78B
57.41%
Rest of the World
853.00M
27.44%
Europe
598.00M
19.23%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
COVID
3.08B
99.20%
RSV
25.00M
0.80%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Tipos de investidores
Investidores
Proporção
Investment Advisor
30.69%
Investment Advisor/Hedge Fund
25.30%
Hedge Fund
7.51%
Corporation
4.68%
Research Firm
4.38%
Individual Investor
2.56%
Bank and Trust
2.36%
Pension Fund
1.27%
Venture Capital
1.21%
Other
20.04%
Participação acionária institucional
Atualizado em: seg, 20 de jan
Atualizado em: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
2090
308.33M
79.76%
-16.50M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
2022Q4
2442
300.08M
77.99%
-2.96M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
40.18M
10.39%
+101.25K
+0.25%
Dec 31, 2024
Baillie Gifford & Co.
38.89M
10.06%
-3.57M
-8.40%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.38M
4.75%
+1.28M
+7.51%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
18.04M
4.67%
+471.49K
+2.68%
Dec 31, 2024
State Street Global Advisors (US)
17.58M
4.55%
+730.02K
+4.33%
Dec 31, 2024
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Geode Capital Management, L.L.C.
7.24M
1.87%
+171.77K
+2.43%
Dec 31, 2024
Theleme Partners LLP
7.31M
1.89%
+80.00K
+1.11%
Dec 31, 2024
OCHA, L.L.C.
6.56M
1.7%
--
--
Mar 05, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
Global X Genomics & Biotechnology ETF
3.72%
Langar Global HealthTech ETF
3.53%
First Trust NYSE Arca Biotechnology Index Fund
3.1%
iShares Genomics Immunology and Healthcare ETF
2.86%
VanEck Biotech ETF
2.08%
SPDR S&P Biotech ETF
1.84%
WisdomTree BioRevolution Fund
1.64%
Federated Hermes MDT Large Cap Value ETF
1.43%
Invesco S&P 500 Equal Weight Health Care ETF
1.28%
ROBO Global Healthcare Technology & Innovation ETF
1.27%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção3.72%
Langar Global HealthTech ETF
Proporção3.53%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.1%
iShares Genomics Immunology and Healthcare ETF
Proporção2.86%
VanEck Biotech ETF
Proporção2.08%
SPDR S&P Biotech ETF
Proporção1.84%
WisdomTree BioRevolution Fund
Proporção1.64%
Federated Hermes MDT Large Cap Value ETF
Proporção1.43%
Invesco S&P 500 Equal Weight Health Care ETF
Proporção1.28%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.27%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
